Please assess the completion status of the following clinical trial:

Trial Title: Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent vestibulopathy patient with symptoms more than 3 months of recurrent vertigo~* Visual analogue scale (VAS) score between 4 to 8~Exclusion Criteria:~* Showing signs of central lesion in MRI or neurologic exams~* central nystagmus or loss of consciousness with vertigo~* cerebellar symptoms such as ataxia, dysarthria, gait disturbance~* Diagnosed as peripheral vertigo such as benign paroxysmal positional vertigo, Meniere's disease, migrainous vertigo in recent 3 months~* Bilateral vestibular dysfunction~* Vestibular neuronitis symptom appeared in recent 6 months~* Chronic liver disease (ALT\>100 or AST\>100) or chronic kidney disease (Creatinine \> 3.0 mg)~* Blood Hemoglobin \< 10mg/dl (in male) or \< 8 mg/dl (in female)~* Contraindication for testing drug (ex. Pregnancy or breast feeding etc.)~* Taking antiepileptics such as phenobarbital, phenytoin, carbamazepine or rifampin in recent 2 weeks~* Taking cilostazol, gingko biloba for other disease~* Allergy/hypersensitivity to Renexin~* Severe drug toxicity when taking Renexin previously

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renexin (Type: ACTIVE_COMPARATOR): Renexin 1T bid for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 1T bid for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).